NasdaqGS - Nasdaq Real Time Price ? USD Ionis Pharmaceuticals, Inc. (IONS) Follow Compare 37.84 -0.79 (-2.05%) At close: October 15 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Ionis Pharmaceuticals, Inc.?(IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds We recently compiled a list of the 10 Stocks with Biggest Upside Potential According to Hedge Funds. In this article, we are going to take a look at where Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands against the other stocks with biggest upside potential. The US equities saw a strong move after the September jobs report exceeded the economists’ estimates. […] Insider Monkey ? 6 days ago IONS -2.05% New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-na?ve to nusinersen Investigational regimen also shows more rapid slowing of neurodegeneration, as measured by neurofilamentBiogen plans to submit regulatory applications around the world for approval of the nusinersen higher dose regimen CAMBRIDGE, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BII GlobeNewswire ? 7 days ago BIIB IONS -2.05% New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new three-year data from the Phase 2 open-label extension (OLE) study as well as additional results from the pivotal Phase 3 OASIS and OASISplus studies of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Results will be presented at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Boston, Massachusetts. PR Newswire ? 13 days ago IONS -2.05% IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag The FDA bestows a Fast Track designation to Ionis' investigational candidate, zilganersen, for treating a rare neurological disorder called Alexander disease. Zacks ? 13 days ago IONS -2.05% Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted zilganersen Fast Track designation for the treatment of children and adults with an ultra-rare, progressive and ultimately fatal neurological disorder known as Alexander disease (AxD). Topline data from the pivotal study of zilganersen is expected in the second half of 2025. The FDA grants investigational medicines Fast Track designation to facilitate the development and expedi PR Newswire ? 15 days ago IONS -2.05% The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly The drugmaker’s fastest-growing blockbuster could soon face competition from two biotech firms in the treatment of a little-known heart condition. The Wall Street Journal ? last month NTLA +0.05% PFE ALNY +1.43% Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price. Zacks ? last month IONS -2.05% AZN NVS Ionis announces pricing of $500.3 million public offering Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock. The shares of common stock are being sold at a public offering price of $43.50 per share. The aggregate gross proceeds to Ionis from this offering are expected to be approximately $500.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Ionis. Ionis has granted the underwriters a 30-day PR Newswire ? last month IONS -2.05% Ionis announces proposed public offering of common stock Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock. Ionis intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock offered in the public offering on the same terms and conditions. Ionis intends to use the net proceeds from the offering to fund its independent commercial launches, late-stage clinical programs, earlier pipeline programs, and res PR Newswire ? last month IONS -2.05% Why Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report? Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks ? last month ZTS IONS -2.05% Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue? Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks ? last month TBPH IONS -2.05% Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the International League Against Epilepsy (ILAE) 15th European Epilepsy Congress (EEC), b GlobeNewswire ? last month PRAX IONS -2.05% Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational dose regimenHigher dose nusinersen regimen showed statistically significant improvement compared to a prespecified matched sham control groupAmong key measures of clinical efficacy, higher dose regimen showed positive trends compared to the approved dosing regimen CAMBRIDGE, Mass., Sept. 04, 2024 (GLOB GlobeNewswire ? last month IONS -2.05% BIIB Ionis to present at upcoming investor conferences Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: PR Newswire ? last month IONS -2.05% Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth? Ionis (IONS) enjoys a diverse revenue stream, including numerous sources of collaborative and R&D revenues. These funds enable it to invest in the development of its wholly-owned pipeline. Zacks ? last month IONS -2.05% AZN NVS Insider Sale at Ionis Pharmaceuticals Inc (IONS) by EVP, Chief Development Officer Richard Geary Following this sale, the insider now owns 85,508 shares of Ionis Pharmaceuticals Inc. Over the past year, Richard Geary has sold a total of 32,954 shares and has not made any purchases of the company's stock. The shares of Ionis Pharmaceuticals Inc were priced at $48 on the day of the sale, giving the company a market cap of approximately $6.88 billion. GuruFocus.com ? 2 months ago IONS -2.05% Ionis Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations Ionis Pharmaceuticals ( NASDAQ:IONS ) Second Quarter 2024 Results Key Financial Results Revenue: US$225.0m (up 19% from... Simply Wall St. ? 2 months ago IONS -2.05% Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises Ionis (IONS) reports better-than-expected top and bottom-line numbers for the second quarter of 2024. Zacks ? 2 months ago IONS -2.05% AZN Q2 2024 Ionis Pharmaceuticals Inc Earnings Call Q2 2024 Ionis Pharmaceuticals Inc Earnings Call Thomson Reuters StreetEvents ? 2 months ago IONS -2.05% AZN NVS Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Zacks ? 2 months ago IONS -2.05% Performance Overview Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return IONS S&P 500 YTD -25.20% +21.92% 1-Year -21.13% +34.37% 3-Year +9.71% +31.03%
